{
    "clinical_study": {
        "@rank": "48756", 
        "arm_group": {
            "arm_group_label": "Vismodegib", 
            "arm_group_type": "Experimental", 
            "description": "Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year."
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm pharmacodynamic study with mandatory metastatic tumor biopsies in men\n      with castration-resistant prostate cancer.\n\n      The trial will  evaluate the effect of vismodegib on tumor tissue in men with metastatic\n      CRPC by obtaining tumor biopsies at baseline and after 4 weeks of treatment with vismodegib."
        }, 
        "brief_title": "A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study will enroll 10 evaluable patients. Patients will receive a 30-day supply of 150 mg\n      of vismodegib on day one of each cycle daily by mouth, beginning on Day 1, and continuously\n      until one of the following occurs: Disease progression, intolerable toxicity most probably\n      attributable to vismodegib or withdrawal from the study.\n\n      Tumor biopsies (nodal or visceral), skin biopsies, and CTCs will be obtained at baseline and\n      after 4 weeks of treatment. PSA evaluations will be conducted every 4 weeks, imaging\n      assessments (CT and Bone scan) will be conducted every 12 weeks and routine labs (blood\n      counts and chemistry panel) will be conducted every 4 weeks.\n\n      The investigator's intent is to examine the fold change in GLI1 expression in each man\n      following exposure to drug (comparing pre-treatment and on-treatment core biopsy samples).\n      As secondary endpoints, the investigator will also explore clinical response (PSA responses,\n      progression-free survival [PFS], radiographic responses), safety, and will examine changes\n      from baseline in Gli2, PTCH1, and AKT1 mRNA levels by qRT-PCR, in situ GLI1 expression in\n      tissue sections by mRNA in situ hybridization, and GLI1 expression in isolated circulating\n      tumor cells (CTCs)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men with metastatic castration-resistant prostate cancer (mCRPC), with accessible\n             metastatic soft-tissue lesions for tumor biopsy\n\n          -  Greater than 18 years of age\n\n          -  Evidence of disease progression (PSA progression, or radiographic/clinical\n             progression [PCWG2])\n\n               -  PSA progression is defined as at least two consecutive rises in serum PSA,\n                   obtained at a minimum of 1-week intervals, and each value \u2265 2.0 ng/mL.\n\n               -  Radiographic progression is defined for soft tissue lesions using RECIST\n                  criteria, i.e. an increase greater than 20% in the sum of the longest diameter\n                  of all target lesions based on the smallest sum longest diameter since treatment\n                  started or the appearance of one of more new lesions with a confirmatory scan 6\n                  or more weeks later. Radiographic progression will be defined for bone lesions\n                  as the appearance of two new lesions with a confirmatory scan performed 6 or\n                  more weeks later that shows at least 2 or more additional new lesions.\n\n          -  Presence of \u22651 metastatic site (nodal, visceral) that is amenable to core biopsy\n\n          -  Castrate serum testosterone (<50 ng/dL)\n\n          -  Prior anti-androgens are permitted but not required (2 week washout from\n             anti-androgens)\n\n          -  Prior abiraterone and enzalutamide are permitted (2 week washout for both agents)\n\n          -  Prior immunotherapy (e.g. sipuleucel-T), and chemotherapy are permitted (4 week\n             washout period from chemotherapy)\n\n          -  Bisphosphonates and denosumab are permitted, if on a stable dose for \u22654 weeks\n\n          -  Life expectancy \u226512 months\n\n          -  Adequate renal, liver, and bone marrow function with the following acceptable initial\n             laboratory values:\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be \u2264\n                  2.5 x the upper limit of normal (ULN).\n\n               -  Total bilirubin must be \u2264 1.5 x ULN.\n\n               -  Estimated creatinine clearance using the Cockcroft-Gault formula must be > 40\n                  mL/minute (See section 12.2 for formula)\n\n               -  Absolute neutrophil count (ANC) must be \u2265 1500/\u03bcL\n\n               -  Platelet count must be \u2265 100,000/\u03bcL\n\n          -  Willing and able to provide written informed consent and HIPAA authorization for the\n             release of personal health information.\n\n        NOTE: HIPAA authorization may be either included in the informed consent or obtained\n        separately.\n\n          -  Karnofsky Performance status/ECOG Performance Status \u226570/2 (Appendix A: Performance\n             Status Criteria)\n\n          -  Male patients must use condoms at all times, even after a vasectomy, during sexual\n             intercourse with female partners of reproductive potential during treatment with\n             vismodegib and for 2 months after the last dose to avoid exposing a pregnant partner\n             and unborn fetus to vismodegib.\n\n        Exclusion Criteria:\n\n          -  Current use of systemic corticosteroids (>5 mg prednisone)\n\n          -  Known brain metastases, or untreated meningeal/dural disease\n\n          -  Receiving any other investigational agents or receipt of another investigational\n             agent within 4 weeks of study entry\n\n          -  Patients taking anticoagulants or with a history of a bleeding diathesis (due to need\n             for visceral biopsy)\n\n          -  Use of any prohibited concomitant medications (washout period of 1 week)\n\n          -  Insufficient time from last prior regimen or radiation exposure (washout period of 4\n             weeks)\n\n          -  Grade > 2 treatment-related toxicity from prior therapy\n\n          -  Any other condition which, in the opinion of the Investigator, would preclude\n             participation in this trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115828", 
            "org_study_id": "J1423", 
            "secondary_id": "NA_00093427"
        }, 
        "intervention": {
            "arm_group_label": "Vismodegib", 
            "intervention_name": "Vismodegib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Vismodegib", 
            "Metastatic Castration-Resistant Prostate Cancer", 
            "Accessible Metastatic Lesions for Tumor Biopsy"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "Rharb1@jhmi.edu", 
                "last_name": "Rana Harb, MS", 
                "phone": "443-287-6662"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hospital"
            }, 
            "investigator": {
                "last_name": "Emmanuel Antonarakis, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy", 
        "overall_contact": {
            "email": "Rharb1@jhmi.edu", 
            "last_name": "Rana Harb, MS", 
            "phone": "443-287-6662"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Emmanuel Antonarakis, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the proportion of mCRPC patients treated with vismodegib who achieve a pharmacodynamic (PD) response in tumor biopsies, defined as both a decrease in GLI1 mRNA greater than 1.2 times the standard deviation (SD) of the baseline values and a \u226550% (\u22652-fold) reduction in GLI1 mRNA expression in metastatic tumor biopsies after 4 weeks of treatment when comparing post-treatment biopsy to pre-treatment biopsy in the same patient.", 
            "measure": "The proportion of mCRPC patients treated with vismodegib who achieve a pharmacodynamic (PD) response in tumor biopsies", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Suppression by vismodegib in tumor tissue of Hh-regulated transcripts and proteins will be defined as the change from baseline in expression levels of GLI1, GLI2, PTCH1, and AKT1 mRNA levels by qRT-PCR, and GLI1 in situ tissue expression by mRNA in situ hybridization. Measurements will be made on the pre-treatment biopsy and post-treatment biopsy for each patient.", 
                "measure": "Suppression by vismodegib in tumor tissue of Hh-regulated transcripts", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 Year"
            }, 
            {
                "description": "Suppression by vismodegib in markers of the Hh pathway in skin punch-biopsies will be defined as the change from baseline in GLI1, GLI2, PTCH1 mRNA levels by qRT-PCR levels in skin punch-biopsies. Measurements will be made on the pre-treatment biopsy and post-treatment biopsy for each patient.", 
                "measure": "Suppression by vismodegib in markers of the Hh pathway in skin punch-biopsies", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 Year"
            }, 
            {
                "description": "Suppression by vismodegib in CTCs of the Hh pathway and AR pathway will be defined as the change from baseline in GLI1, AKT1, AR, FOLH1, and KLK3 mRNA levels in CTCs before and 4 weeks after treatment", 
                "measure": "Suppression by vismodegib in CTCs of the Hh pathway and AR pathway", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 Year"
            }, 
            {
                "description": "The effect of vismodegib on PSA responses will be assessed as the proportion of patients with PSA responses with \u226530% PSA reductions, and \u226550% PSA reductions at any time point during study", 
                "measure": "The effect of vismodegib on PSA responses", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 Year"
            }, 
            {
                "description": "The safety/tolerability and drug-related toxicities of vismodegib will be assessed via CTCAE version 4.0 criteria and tabulated", 
                "measure": "The safety/tolerability and drug-related toxicities of vismodegib", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 Year"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}